Ventricular tachyarrhythmia during pregnancy in women with heart disease: data from the ROPAC, a registry from the European Society of Cardiology.

Ebru Ertekin BSc¹, Iris M. Van Hagen MD¹, Amar M. Salam MD², Titia P.E. Ruys MD PhD¹, Mark R. Johnson MD PhD³, Jana Popelova MD PhD⁴, William A. Parsonage, MD⁵, Zeinab Ashour MD⁶, Avraham Shotan MD⁷, José M. Oliver MD, PhD⁸, Gruschen R. Veldman MD⁹, Roger Hall MD PhD¹⁰, Jolien W. Roos-Hesselink MD PhD¹¹.*

Ventricular tachyarrhythmia during pregnancy

¹ Erasmus University Medical Center, Rotterdam, The Netherlands
² Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
³ Imperial College School of Medicine, Chelsea and Westminster Hospital, London, United Kingdom
⁴ Hospital Na Homolce & Pediatric Heart Center University Hospital Motol, Prague, Czech Republic
⁵ Royal Brisbane & Women’s Hospital, Herston, Australia
⁶ Cairo University, Cairo, Egypt
⁷ Hillel Yaffe Medical Center, Hadera, Israel
⁸ Adult Congenital Heart Disease Unit, La Paz University Hospital, Madrid, Spain
⁹ Adolescent and Adult Congenital Heart Program, Cincinnati Children’s Hospital, Cincinnati, United States
¹⁰ Norwich Medical School, University of East Anglia, Norwich, United Kingdom
¹¹ Fellow of the European Society of Cardiology, Sophia Antipolis Cedex, France.
*Corresponding author
Jolien W. Roos-Hesselink, MD, PhD
Email: j.roos@erasmusmc.nl
Postal address: Department of Cardiology, office Ba 308
Erasmus University Medical Center
PO Box 2040, 3000 CA Rotterdam, The Netherlands
Tel: +31 10 70 32 432 / Fax: +31 10 70 35 498

Total word count: 4289 words

Funding sources: The ROPAC is a registry within the EURObservational Research Programme (EORP) of the European Society of Cardiology. Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011-2014), Amgen (2012-2015), AstraZeneca (2014-2017), Bayer Pharma AG (2013-2015), Boehringer Ingelheim (2013-2016), Boston Scientific (2010-2012), The Bristol Myers Squibb and Pfizer Alliance (2014-2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014-2017), Gedeon Richter Plc. (2014-2017), Menarini Int. Op. (2010-2012), MSD-Merck & Co. (2011-2014), Novartis Pharma AG (2014-2017), ResMed (2014-2016), Sanofi (2010-2011), SERVIER (2012-2015). The companies that support EORP were not involved in any part of the study or this report. The authors have no personal disclosures with regard to this article.
Abstract

Objectives: To describe the incidence, onset, predictors and outcome of ventricular tachyarrhythmia (VTA) in pregnant women with heart disease.

Background – VTA during pregnancy will cause maternal morbidity and even mortality and will have impact on fetal outcome. Insufficient data exist on the incidence and outcome of VTA in pregnancy.

Methods and Results – From January 2007 up to October 2013, 99 hospitals in 39 countries enrolled 2966 pregnancies in women with structural heart disease. Forty-two women (1.4%) developed clinically relevant VTA during pregnancy, which occurred mainly in the third trimester (48%). NYHA class >1 before pregnancy was an independent predictor for VTA. Heart failure during pregnancy was more common in women with VTA than in women without VTA (24% vs. 12%, p=0.03) and maternal mortality was respectively 2.4% and 0.3% (p=0.15). More women with VTA delivered by Caesarean section than women without VTA (68% vs. 47%, p=0.01). Neonatal death, preterm birth (<37 weeks), low birthweight (<2500 gram) and Apgar score <7 occurred more often in women with VTA (4.8% vs. 0.3%, p=0.01; 36% vs. 16%, p=0.001; 33% vs. 15%, p=0.001 and 25% vs. 7.3%, p=0.001, respectively).

Conclusions – VTA occurred in 1.4% of pregnant women with cardiovascular disease, mainly in the third trimester, and was associated with heart failure during pregnancy. NYHA class before pregnancy was predictive. VTA during pregnancy had clear impact on fetal outcome.

Condensed abstract:

We examined ventricular tachyarrhythmia (VTA) during pregnancy and its impact on maternal and fetal outcomes using data on 2966 pregnancies in women with heart disease from the Registry Of Pregnancy And Cardiac disease (ROPAC). The incidence of VTA was 1.4% and occurred mainly in the third trimester (48%). NYHA class>1 before pregnancy was an independent pre-pregnancy predictor for VTA. VTA was associated with higher rates of heart failure (24% vs. 12%, p=0.03),
neonatal death (4.8% vs. 0.3%, p=0.01), preterm birth (36% vs. 16%, p=0.001), low birthweight (33% vs. 15%, p=0.001) and poor Apgar score (25% vs. 7.3%, p=0.001).
**Abbreviations**

AOP = Aortic pathology  
CHD = Congenital heart disease  
CMP = Cardiomyopathy  
IHD = Ischemic heart disease  
NYHA = New York Heart Association  
VHD = Valvular heart disease  
VTA = Ventricular tachyarrhythmia
Introduction

Heart disease is an important cause of maternal death and, surprisingly, rates are increasing (1,2). Interim analysis of the Registry Of Pregnancy and Cardiac disease (ROPAC) reported a 100 times higher maternal mortality rate in women with heart disease compared to the general pregnant population (3). This raises serious safety concerns for women with structural heart disease and makes it imperative to identify those at greatest risk of complications during pregnancy.

Potentially life-threatening ventricular tachyarrhythmia (VTA) is rare during normal pregnancy (2 per 100,000 pregnancies) (4,5), but may be associated with maternal hemodynamic compromise causing adverse consequences for both mother and fetus (6). This data, particularly in women with structural heart disease, however is scarce and is generally poorly reported in the literature. The incidence of VTA in pregnant women with heart disease has been documented ranging from 1.0% to 1.4% (1,7). In patients with congenital heart disease, VTA occurs in up to 1.6% (1,8), whereas there are hardly any reports on the incidence of VTA in pregnant women with valvular heart disease, ischemic heart disease or cardiomyopathy. Also, insufficient data exist on the outcome of VTA during pregnancy. Previous studies mostly report on arrhythmias in general, but it is of major importance to distinguish potentially life-threatening VTA from the mostly benign supraventricular tachycardia. This study describes the incidence, onset, predictors and outcome of VTA during pregnancy in women with structural heart disease.

Methods

Study design

The Registry Of Pregnancy And Cardiac disease (ROPAC) is part of the EUObservational Research Programme (EORP of the European Society of Cardiology) and was initiated in 2007. From January 2008 pregnant women with heart disease were included prospectively. Patients from 2007 were included retrospectively, assuming that the complete data were available and reliable. All patients included up to October 2013 were included in the current interim analysis. In this period, 99 hospitals in 39 countries contributed to the registry and a total of 2966 pregnant women with congenital heart disease (CHD), valvular heart disease (VHD), cardiomyopathy (CMP), ischemic heart disease (IHD),
aortic pathology (AOP) or pulmonary hypertension were enrolled. Non-structural heart disease, for example arrhythmia occurring in the context of a structurally normal heart, was excluded. The study protocol and first results of this registry were published in 2013 (3).

Data

VTA has been defined as three or more consecutive ventricular beats with a mean rate of more than 100 beats per minute; however, only clinically relevant VTA (when the patient had physical complaints, needed treatment for VTA or when the patient had more than 100 consecutive beats) was included. Onset of VTA, given in weeks of gestation, was calculated using the expected date of delivery. Data up to one week after delivery was available for all patients. Baseline characteristics before pregnancy were analyzed, including cardiac diagnosis, maternal age, parity, clinical signs of heart failure, hypertension, smoking status, medication use and New York Heart Association (NYHA) functional class. The following cardiac diagnoses were included: CHD, VHD, IHD, CMP, AOP and pulmonary hypertension. The type of cardiac lesions were divided into three categories for the univariable logistic regression analysis: right sided lesions (e.g. Ebstein anomaly, tetralogy of Fallot, pulmonary stenosis), left sided lesions (e.g. aortic valve disease, mitral valve disease and most cardiomyopathies) and shunt lesions (e.g. atrial septal defects and ventricular septal defects). Participating countries were classified as developed or developing according to the International Monetary Fund classification (9).

Statistical methods

Categorical data are presented as frequencies (numbers) and percentages. Normality of continuous data was checked by one-sample Kolmogorov-Smirnov tests and histograms. Continuous data are presented as mean values +/- one standard deviation (SD) when normally distributed. The chi-squared test was used to compare differences in categorical data between independent patient groups. Fisher’s exact tests were applied if any expected cell count was less than 5. The Student’s t-test was used to compare differences in continuous data between independent patient groups. Mean birthweight was corrected for gestational age, fetal sex, maternal age and diabetes, using linear regression. The
birthweight was not normally distributed; therefore both the median birthweight and the corrected mean birthweight are shown in this article. Baseline patient characteristics associated with VTA were identified with univariable logistic regression analysis. Available echocardiographic data (moderate or severely impaired systemic ventricular function) were also analyzed in the univariable logistic regression analysis. The multivariable analysis consists of variables that were associated with an increased incidence of the studied endpoint (P<0.15). For each 10 cases/patients, one of the most significant univariable predictors was included in the multivariable analysis. A p-value <0.05 (2-sided test) was considered statistically significant. All statistical analyses were performed using SPSS 21.0 (SPSS Inc., Chicago).

Results

Baseline characteristics

Of the 2966 patients included in the registry, 42 (1.4%) patients developed clinically relevant VTA during pregnancy. One patient had ventricular fibrillation (VF), the other patients had ventricular tachycardia. Baseline characteristics of pregnant patients with and without VTA are shown in Table 1. The incidence of VTA was 1.2% in CHD patients, 0.6% in VHD patients, 5.9% in CMP patients, 2.1% in IHD patients and 3.0% in AOP patients. VTA was not observed in patients with pulmonary hypertension. The diagnoses per cardiac disease category are shown in Figure 1. Before pregnancy, three patients had pacemaker-dependent rhythm. All others were in sinus rhythm.

Onset of VTA

Figure 2 shows that VTA mainly occurred in the third trimester (48%). Figure 3 shows the onset of VTA per cardiac disease category.

Predictors

The results of the univariable and multivariable logistic regression are shown in Table 2.

Medication before and during pregnancy
Of the 42 patients with VTA, 31% used cardiac medication before pregnancy. The medication used before pregnancy is shown in Table 1. During pregnancy, 74% of the VTA patients used medication: 57% used beta-blockers, 12% used other anti-arrhythmic drugs and 12% used diuretics. Amiodarone was used in 3 of the 42 patients with VTA.

Maternal outcome

Pregnancy outcome until one week after delivery is presented in Table 3. Heart failure was diagnosed in 10 VTA patients (24%), occurring after VTA in three patients, before in three and at the same time in one and in the remaining three patients the temporal relationship was unclear. Maternal death occurred in one patient (2.4%). This was a 36-year-old woman with pulmonary atresia, who had a bioprosthetic pulmonary valve replacement before pregnancy. She was taking beta-blockers because of aortic dilatation and used LMWH throughout pregnancy. At 17 weeks of pregnancy, she had an out of hospital cardiac arrest due to VF. She survived resuscitation, but was left in a persistent vegetative state. She was ventilated until delivery at 32 weeks and died one week postpartum.

Delivery and fetal outcome

Fetal outcome is shown in Table 3. Mode of delivery in patients with VTA was by emergency Caesarean section in 20%, elective Caesarean section in 48% and vaginally in 32%. No fetal death occurred in VTA patients (Table 3), but there were two neonatal deaths. A 28-year-old patient with non-obstructive CMP developed VTA in week 6 of pregnancy. She underwent Caesarean section at 29 weeks for cardiac reasons, followed by an unexplained neonatal death. The second neonatal death was due to acute respiratory distress syndrome (ARDS) one week postpartum. The mother of this child had subaortic stenosis and a history of heart failure before pregnancy.

Discussion

This is the first detailed study of pregnancy outcome after VTA in patients with cardiovascular disease. In this large prospective international registry of 2966 pregnancies with heart disease, the incidence of VTA during pregnancy was 1.4% and occurred mainly in the third trimester. NYHA class
>1 before pregnancy was an independent predictor of VTA. VTA was associated with a marked increase in the neonatal death rate, preterm birth rate, low birthweight rate and poor Apgar score.

**Incidence of VTA**

Existing data on the incidence of VTA during pregnancy in patients with heart disease is scarce. Siu et al. studied pregnancy outcome in two cohorts of women with heart disease. VTA occurred in 4 cases in the cohort of 276 pregnancies and in 6 patients in the cohort of 599 pregnancies (1,7). The incidence of VTA in our study (1.4%) was comparable to the incidence of Siu et al.’s retrospective (1.4%) and prospective (1.0%) studies.

**Congenital heart disease** – VTA during pregnancy in women with CHD is rare. We observed VTA in 1.2% of CHD patients, in keeping with the reported incidence range from 0.4 to 1.6% (1,8). Patients with repaired CHD in the study of Niwa et al. (10) had a significantly higher incidence of VTA than healthy pregnant women. In their study, the prevalence of non-sustained VTA was 14% with the highest incidence in patients with previous surgical correction of Tetralogy of Fallot (TOF) (8,10,11). In our study, VTA occurred in 2.5% of TOF patients (3 out of 119 patients), however, we only included patients with symptomatic VTA.

**Cardiomyopathy** – VTA occurred remarkably often in patients with CMP (7.4%) in our study. In the study of Grewal et al. (12), VTA occurred in 3% of dilated CMP patients. In patients with hypertrophic CMP, the incidence of arrhythmias (including VTA) was not increased during pregnancy (13). However, in hypertrophic CMP patients with an Implantable Cardioverter Defibrillator (ICD), VTA is a common complication with an observed incidence of 22% during pregnancy (14). Some case reports of VTA in patients with peripartum cardiomyopathy (PPCM) have been published previously (15-17). In our study VTA did not occur in the 33 PPCM patients.

**Valvular heart disease** – We found that 0.7% of the patients with VHD developed VTA during pregnancy and the majority had mitral valve disease. In the literature, ventricular arrhythmia, not further defined, has been described in 1.5% of pregnant women with VHD (18) and occurred in 1.2% in Siu et al.’s prospective study.
Ischemic heart disease – Although seldom encountered during pregnancy, IHD is a major and increasing cause of maternal death (19). In the existing literature, cases of VF, but not ventricular tachycardia, have been reported during pregnancy in patients with a myocardial infarction (20,21). In our registry, VTA occurred in only one patient with IHD (2.1%).

Predictors for VTA

Women with a limited exercise tolerance are at higher risk of developing complications during pregnancy (4), and consequently, we were not surprised to find that NYHA class>1 before pregnancy is an independent predictor of VTA. Any disease process that affects the ventricular myocardium causing hypertrophy, infiltration or scarring may disrupt the electrical integrity of the myocardium and induce VTA (11). CMP in general is known to be associated with ventricular arrhythmias as it is often associated with diminished ventricular function (22). In accordance with this, we found that a diagnosis of CMP showed a borderline significance (0.06) in the multivariable analysis.

Onset during pregnancy

Nakagawa et al. (23) studied 11 pregnant women who experienced a new onset of ventricular tachycardia during pregnancy. In their study, the onset of ventricular tachycardia was distributed equally over the three trimesters and did not occur in the postpartum period. Overall, VTA occurred throughout pregnancy but more in the third trimester in our study, with CHD patients experiencing VTA more in the second and third trimester, while CMP patients typically present with VTA at the end of pregnancy (≥32 weeks), perhaps reflecting a different threshold for VTA. These findings raise a number of hypotheses regarding the mechanism of VTA during pregnancy. Cardiac output, induced by a decline in systemic vascular resistance, rises rapidly through the first and second trimesters reaching a peak at around 26 weeks and remaining at this level until the end of pregnancy (24). The increase in cardiac output is due to an increase in heart rate and stroke volume. The greater filling, resulting in an increase in cardiac end diastolic volumes, will result in myocardial stretch which has been shown to induce VTA (25). In addition to these physiological changes during normal pregnancy, women with structural heart disease have limited ability to adjust to the hemodynamic requirement of pregnancy,
and this may become manifest as systolic and diastolic cardiac dysfunction during pregnancy (24), which again may increase the risk of VTA. Finally, the increased sympathetic activity observed during pregnancy has also been suggested to be responsible for the increased incidence of arrhythmias and it is well known that high plasma catecholamine concentrations and adrenergic receptor sensitivity may trigger VTA (26). In all patients, the hemodynamic overload may well have contributed to the development of VTA, while the increased sympathetic activity may be more important in specific groups such as cardiomyopathy patients, which may be more susceptible.

**Maternal outcome**

VTA, outside of pregnancy, is associated with sudden cardiac death, especially in the presence of cardiomyopathy (22,27). Previous publications on VTA during pregnancy were either case reports or studies which have only reported on its incidence. Therefore, it is not well known whether VTA during pregnancy carries an extra high risk for mortality. We did not detect a significant increase in maternal mortality, but it must be noted that, although our series is by far the largest, our mortality numbers are still small and we have analyzed outcome only until one week after pregnancy. The timing of heart failure and VTA seemed to be associated in our study. However, a clear cut pattern was not found as some patients developed heart failure shortly after VTA, while others developed heart failure prior to VTA.

**Delivery and fetal outcome**

Women with VTA during pregnancy had higher rates of neonatal death, preterm birth and poor Apgar score. Certainly, low birthweight was more common in patients with VTA than in patients without VTA and the median birthweight was significantly lower in VTA patients. However, the corrected mean birthweight did not significantly differ between the two groups, suggesting that the difference in birthweight is primarily due to the higher preterm birth rate. Physicians often opt for preterm delivery in women with VTA, partly to shorten the period of hemodynamic compromise and also to be able to institute a more aggressive therapy for VTA, which might have an adverse effect on the fetus. Equally, the decision for early delivery may have a negative impact on neonatal development (28).
Management of VTA during pregnancy

In general, the management of VTA in pregnancy is similar to that outside of pregnancy. For VTA with hemodynamic compromise, immediate cardioversion, which is reported to be safe in all phases of pregnancy, is recommended (4). When the patient is not hemodynamically compromised, medication should be considered. The concerns with anti-arrhythmic drug use during pregnancy relate to their effects on fetal growth and development. Beta-blockers are the drug of choice for hemodynamically well-tolerated VTA. The use of beta-blockers during pregnancy is generally well tolerated by both mother and fetus, even though it has been associated with a decrease in fetal heart rate, low blood glucose and reduced birthweight (22,29). In our study, most patients with VTA (57%) were treated with a beta-blocker, other antiarrhythmic drugs were prescribed in 12% of the patients. Amiodarone was used in 3 of the 42 patients with VTA in our study and may have had a deleterious effect on one fetus, perhaps causing growth retardation requiring earlier delivery (22). A multidisciplinary approach with close monitoring of mother and baby with timely intervention for both is required to optimize maternal and fetal outcomes.

Implications on clinical practice

The significance of VTA during pregnancy in women with heart disease lies in the fact that it carries a higher preterm birth rate and, consequently, lower birthweight and poor Apgar score. Cardiac patients in NYHA class>1 and patients with CMP are at particular risk and should be counselled about the risks before pregnancy and followed closely during pregnancy.

Limitations

This dataset, like in other registry collected datapoints, was limited by the availability of information on the past history. In our registry missing data concerning the current pregnancy ranged from 0% to 4% for all parameters except two: smoking (14%) and left ventricular dysfunction (36%). Although VTA is an important complication especially in women with underlying heart disease, its incidence is
low, reflected in the number of cases. This makes it difficult to draw any firm conclusions. The severity of the VTAs was not reported in detail.

Acknowledgements

We would like to thank all ROPAC investigators, who are listed in the Supplemental Material online. Our gratitude goes to the EORP team for their contribution, in particular: Elin Folkesson-Lefrancq, Viviane Missiamenou, Gérard Gracia and Myriam Lafay. To join the Registry:

http://www.escardio.org/guidelines-surveys/eorp/surveys/pregnancy/Pages/welcome.aspx.
References

1. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001;104:515-21.
2. Jastrow N, Meyer P, Khairy P, et al. Prediction of complications in pregnant women with cardiac diseases referred to a tertiary center. Int J Cardiol 2011;151:209-13.
3. Roos-Hesselink JW, Ruys TP, Stein JJ, et al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J 2013;34:657-65.
4. European Society of G, Association for European Paediatric C, German Society for Gender M, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147-97.
5. Li JM, Nguyen C, Joglar JA, Hamdan MH, Page RL. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol 2008;31:538-41.
6. Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J 2001;22:458-64.
7. Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997;96:2789-94.
8. Tateno S, Niwa K, Nakazawa M, et al. Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study. Circ J 2003;67:992-7.
9. (WEO) WEO. Growth Resuming, Dangers Remain. 2012:p177-180.
10. Niwa K, Tateno S, Akagi T, et al. Arrhythmia and reduced heart rate variability during pregnancy in women with congenital heart disease and previous reparative surgery. Int J Cardiol 2007;122:143-8.
11. Adamson DL, Nelson-Piercy C. Managing palpitations and arrhythmias during pregnancy. Heart 2007;93:1630-6.
12. Grewal J, Siu SC, Ross HJ, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 2009;55:45-52.
13. Thaman R, Varnava A, Hamid MS, et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. Heart 2003;89:752-6.
14. Schuler PK, Herrey A, Wade A, et al. Pregnancy outcome and management of women with an implantable cardioverter defibrillator: a single centre experience. Europace 2012;14:1740-5.
15. Yahagi N, Kumon K, Nakatani T, et al. Peripartum cardiomyopathy and tachycardia followed by multiple organ failure. Anesth Analg 1994;79:581-2.
16. Gemici G, Tezcan H, Fak AS, Oktay A. Peripartum cardiomyopathy presenting with repetitive monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 2004;27:557-8.
17. Puri A, Sethi R, Singh B, et al. Peripartum cardiomyopathy presenting with ventricular tachycardia: a rare presentation. Indian Pacing Electrophysiol J 2009;9:186-9.
18. Lesniak-Sobelga A, Tracz W, KostKiewicz M, Podolec P, Pasowicz M. Clinical and echocardiographic assessment of pregnant women with valvular heart diseases--maternal and fetal outcome. Int J Cardiol 2004;94:15-23.
19. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the
20. Curry JJ, Quintana FJ. Myocardial infarction with ventricular fibrillation during pregnancy treated by direct current defibrillation with fetal survival. Chest 1970;58:82-4.

21. O'Donnell M, Meecham J, Tosson SR, Ward S. Ventricular fibrillation and reinfarction in pregnancy. Postgrad Med J 1987;63:1095-6.

22. European Heart Rhythm A, Heart Rhythm S, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247-346.

23. Nakagawa M, Katou S, Ichinose M, et al. Characteristics of new-onset ventricular arrhythmias in pregnancy. J Electrocardiol 2004;37:47-53.

24. Cornette J, Ruys TP, Rossi A, et al. Hemodynamic adaptation to pregnancy in women with structural heart disease. Int J Cardiol 2012.

25. Hunter S, Robson SC. Adaptation of the maternal heart in pregnancy. Br Heart J 1992;68:540-3.

26. Trappe HJ, Tchirikov M. [Cardiac arrhythmias in the pregnant woman and the fetus] Herzrhythmusstorungen bei der Schwangeren und beim Fetus. Internist (Berl) 2008;49:788-98.

27. Hohnloser SH, Klingenheben T, Bloomfield D, Dabbous O, Cohen RJ. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. J Am Coll Cardiol 2003;41:2220-4.

28. Gibson AT, Carney S, Cavazzoni E, Wales JK. Neonatal and post-natal growth. Horm Res 2000;53 Suppl 1:42-9.

29. Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. beta-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2012;2.
Figure Legends

**Figure 1: Diagnoses per cardiac disease category.**

*CHD=congenital heart disease, VHD=valvular heart disease, CMP=cardiomyopathy, AOP=aortic pathology*

**Figure 2: The occurrence (onset) of VTA during pregnancy in women with heart disease.**

*VTA=ventricular tachyarrhythmia*

**Figure 3: The occurrence of VTA during pregnancy per cardiac disease category.**

*The number of patients per category is shown between brackets.*

*CHD=congenital heart disease, VHD=valvular heart disease, CMP=cardiomyopathy, AOP=aortic pathology, All cardiac=CHD+VHD+CMP+AOP.*

*The time of onset of VTA was missing in four CHD patients.*
Table 1: Baseline characteristics of cardiac patients with and without VTA*

|                                | Total group | Patients with VTA | Patients without VTA | p-value |
|--------------------------------|-------------|-------------------|----------------------|---------|
| Mean age in years (SD†)        | 29.3 (5.6)  | 28.9 (5.7)        | 29.3 (5.6)           | 0.78    |
| Nulliparity (%)                | 45          | 55                | 45                   | 0.21    |
| Clinical signs of heart failure (%) | 10          | 21                | 10                   | 0.02    |
| Hypertension (%)               | 6.5         | 4.9               | 6.5                  | 1.00    |
| Current smoker (%)             | 4.3         | 5.1               | 4.3                  | 0.68    |
| Developing countries (%)       | 35          | 45                | 35                   | 0.17    |
| **NYHA class‡**                |             |                   |                      | 0.002   |
| NYHA class 1 (%)               | 73          | 50                | 73                   |         |
| NYHA class 2 (%)               | 22          | 38                | 22                   |         |
| NYHA class 3 (%)               | 2.9         | 11.9              | 2.8                  |         |
| NYHA class 4 (%)               | 0.3         | 0                 | 0.3                  |         |
| **Type of heart disease**      |             |                   |                      |         |
| Congenital heart disease (%)   | 56          | 48                | 56                   | 0.28    |
| Valvular heart disease (%)     | 32          | 14                | 32                   | 0.01    |
| Ischemic heart disease (%)     | 1.6         | 2.4               | 1.6                  | 0.68    |
| Cardiomyopathy (%)             | 7           | 29                | 7                    | <0.001  |
| Aortic pathology (%)           | 3.4         | 7.1               | 3.4                  | 0.18    |
| Pulmonary arterial hypertension (%) | 0.4       | 0                 | 0.4                  | 1.00    |
| **Medication use before pregnancy** |         |                   |                      |         |
| Beta-blocker (%)               | 12          | 17                | 12                   | 0.39    |
| Other anti-arrhythmic drugs (%)| 3.1         | 0                 | 3.1                  | 0.64    |
| Diuretics (%)                  | 5.8         | 9.5               | 5.7                  | 0.30    |
| ACE inhibitors§ (%)            | 3.9         | 4.8               | 3.9                  | 0.68    |
| Calcium antagonists (%)        | 0.2         | 0                 | 0.2                  | 0.34    |

* VTA: ventricular tachyarrhythmia
† SD=standard deviation
‡ NYHA class= New York Heart Association functional class
§ ACE inhibitors: Angiotensin-converting enzyme inhibitors
Table 2: Pre-pregnancy predictors for VTA

| Univariable                              | Odds ratio | 95% CI      | p-value |
|------------------------------------------|------------|-------------|---------|
| Congenital heart disease                 | 0.72       | (0.39-1.32) | 0.28    |
| Valvular heart disease                   | 0.35       | (0.15-0.84) | 0.02    |
| Cardiomyopathy                           | 5.76       | (2.90-11.4) | <0.001  |
| Right sided lesion                       | 0.72       | (0.32-1.62) | 0.43    |
| Left sided lesion                        | 1.71       | (0.91-3.20) | 0.09    |
| Shunt lesion                             | 0.61       | (0.26-1.46) | 0.27    |
| NYHA class>1                              | 2.98       | (1.62-5.49) | <0.001  |
| Nulliparity                              | 1.48       | (0.80-2.72) | 0.21    |
| Hypertension                             | 0.74       | (0.18-3.08) | 0.68    |
| Clinical signs of pre-pregnancy heart failure | 2.59   | (1.23-5.47) | 0.01    |
| Developing countries                     | 1.53       | (0.83-2.82) | 0.17    |
| Any medication use before pregnancy      | 1.16       | (0.60-2.24) | 0.66    |
| Beta-blocker use before pregnancy        | 1.43       | (0.63-3.24) | 0.39    |
| *Echo prior to pregnancy*                |            |             |         |
| Systemic ventricular dysfunction         | 4.59       | (1.92-10.96)| 0.001   |

| Multivariable                            | Odds ratio | 95% CI      | p-value |
|------------------------------------------|------------|-------------|---------|
| Cardiomyopathy                           | 2.70       | (0.95-7.69) | 0.06    |
| NYHA class>1                              | 2.64       | (1.12-6.20) | 0.03    |
| Clinical signs of pre-pregnancy heart failure | 0.88 | (0.29-2.64) | 0.82    |
| Systemic ventricular dysfunction         | 2.25       | (0.78-6.48) | 0.13    |
Table 3: Pregnancy outcome in cardiac patients with and without VTA

*Outcome until one week after pregnancy.*

|                                | Total group (n=2966) | Patients with VTA (n=42) | Patients without VTA (n=2924) | p-value |
|--------------------------------|----------------------|--------------------------|-------------------------------|---------|
| Maternal mortality (%)         | 0.4                  | 2.4                      | 0.3                           | 0.15    |
| **Cardiac**                    |                      |                          |                               |         |
| Heart failure (%)              | 13                   | 24                       | 12                            | 0.03    |
| Thromboembolic events (%)      | 0.8                  | 0                        | 0.8                           | 1.00    |
| Endocarditis (%)               | 0.2                  | 0                        | 0.2                           | 1.00    |
| Bleeding during pregnancy (%)  | 6.2                  | 4.8                      | 6.2                           | 1.00    |
| **Obstetric**                  |                      |                          |                               |         |
| Intra-uterine growth retardation (%) | 4.6                  | 4.8                      | 4.6                           | 0.72    |
| Pregnancy induced hypertension (%) | 2.3                  | 0                        | 2.4                           | 0.63    |
| (Pre)eclampsia (%)             | 2.4                  | 0                        | 2.5                           | 0.63    |
| Caesarean section (%)          | 48                   | 68                       | 47                            | 0.01    |
| **Fetal outcome**              |                      |                          |                               |         |
| Miscarriage (<24 weeks; %)     | 2.7                  | 0                        | 2.7                           | 0.26    |
| Late fetal death (≥24 weeks; %) | 0.7                  | 0                        | 0.7                           | 1.00    |
| Neonatal death (%)             | 0.3                  | 4.8                      | 0.3                           | 0.01    |
| Median pregnancy duration (weeks) | 38.2                 | 37.4                     | 39.0                          | <0.001  |
| Apgar score <7 (%)             | 7.6                  | 25                       | 7.3                           | 0.001   |
| Preterm birth (<37 weeks; %)   | 16                   | 36                       | 16                            | 0.001   |
| Low birthweight (<2500 g; %)   | 15                   | 33                       | 15                            | 0.001   |
| Median birthweight (g)         | -                    | 2730                     | 3020                          | 0.006   |
| Corrected mean birthweight (g)* | -                    | 3283                     | 3289                          | 0.94    |

*Birthweight corrected for: gestational age, fetal sex, maternal age, and diabetes.*
VTA patients (n=42)

CHD (n=20)
- Eisenmenger syndrome (n=3)
- Tetralogy of Fallot (n=3)
- Transposition of the great arteries (TGA, n=2)
- Congenitally corrected TGA (n=1)
- Mitral valve abnormality (n=3)
- Aortic stenosis with bicuspid aortic valve (n=1)
- Subvalvular aortic stenosis with aortic regurgitation (n=1)
- Pulmonary atresia (n=1)
- Pulmonary valve abnormality (n=1)
- Secundum atrial septal defect (n=2)
- Ventricular septal defect, perimembranous (n=1)
- Infundibular stenosis with ASD (n=1)

CMP (n=12)
- Hypertrophic obstructive CMP (n=5)
- Dilated CMP (n=4)
- Arrhythmogenic right ventricular cardiomyopathy (n=2)
- Other unspecified CMP (n=1)

VHD (n=6)
- Mitral regurgitation (n=4)
- Mitral stenosis and mitral regurgitation (n=1)
- Aortic stenosis (n=1)

AOP (n=3)
- Marfan syndrome (n=1)
- Aortic dilatation with a bicuspid aortic valve (n=1)
- Aortic dilatation with unknown reason (n=1)

IHD (n=1)
- ST segment elevation myocardial infarction developed during pregnancy (n=1)
Patients with VTA during pregnancy (%)

Weeks of pregnancy
Patients with VT during pregnancy (%)

Subgroup of heart disease

- CHD (n=16)
- VHD (n=6)
- CMP (n=13)
- AOP (n=3)
- All cardiac (n=38*)

First trimester
Second trimester
Third trimester